Quick-Med Technologies, Inc. (QMDT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerQuick-Med Technologies, Inc. (QMDT) trades at $0.0005. Quick-Med Technologies, Inc. is a life sciences company focused on developing and commercializing proprietary technologies in the medical and consumer healthcare markets. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for QMDT: QMDT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Quick-Med Technologies, Inc. (QMDT) Healthcare & Pipeline Overview
Quick-Med Technologies, Inc. operates in the specialty drug manufacturing sector, focusing on antimicrobial and hemostatic technologies. The company's NIMBUS, Stay Fresh, and MultiStat platforms target diverse applications in healthcare, textiles, and personal care, serving both government and commercial clients with specialized biomedical solutions.
What Is the Investment Thesis for QMDT?
Quick-Med Technologies, Inc. presents a speculative investment opportunity within the specialty drug manufacturing sector. The company's proprietary NIMBUS, Stay Fresh, and MultiStat technologies offer potential for growth in diverse markets, including healthcare, textiles, and personal care. With a negative P/E ratio of -0.02 and a negative profit margin of -76.8%, the company's financial performance indicates it is not currently profitable. A gross margin of 69.8% suggests strong potential profitability if sales volume increases. Key catalysts include successful commercialization of their technologies and partnerships with larger industry players. However, the company's small size (5 employees) and OTC market listing introduce significant risks related to liquidity and operational scalability. The beta of -39.80 suggests an inverse correlation with the market, but this may be unreliable due to the company's limited trading volume.
Based on FMP financials and quantitative analysis
QMDT Key Highlights
Gross Margin of 69.8% indicates strong potential profitability if sales volume increases.
- Negative P/E ratio of -0.02 reflects current lack of profitability.
- Profit Margin of -76.8% indicates significant losses relative to revenue.
- The company has 5 employees, highlighting its small size and potential operational constraints.
- Beta of -39.80 suggests an inverse correlation with the market, but may be unreliable due to limited trading volume.
Who Are QMDT's Competitors?
QMDT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.46 | -5.84% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.24 | -3.06% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.46 | -0.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.81 | +1.46% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.12 | -3.01% | $25.5M | — |
| YI 111, Inc. | $3.17 | -1.55% | $28.1M | 39 5-pillar |
| PETS PetMed Express, Inc. | $1.32 | -3.05% | $29.1M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are QMDT's Key Strengths?
Proprietary NIMBUS, Stay Fresh, and MultiStat technologies.
- Potential for diverse applications in healthcare, textiles, and personal care.
- Existing relationships with government agencies.
- High gross margin (69.8%) indicates potential for profitability.
What Are QMDT's Weaknesses?
Small size and limited resources (5 employees).
- Negative profit margin (-76.8%) indicates significant losses.
- OTC market listing introduces liquidity and regulatory risks.
- Limited brand recognition and market presence.
What Are the Key Risks for QMDT?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Limited financial resources and negative profitability.
- Intense competition from larger pharmaceutical and healthcare companies.
- Stringent regulatory requirements and lengthy approval processes.
- OTC market listing introduces liquidity and regulatory risks.
- Dependence on key personnel and potential loss of intellectual property.
What Are QMDT's Competitive Advantages?
- Proprietary Technologies: Patented NIMBUS, Stay Fresh, and MultiStat technologies provide a competitive edge.
- Specialized Expertise: Focus on antimicrobial and hemostatic solutions creates a niche market position.
- Established Relationships: Existing relationships with government agencies and healthcare providers offer a stable customer base.
What Does QMDT Do?
Founded in 1997 and headquartered in Gainesville, Florida, Quick-Med Technologies, Inc. is a life sciences company dedicated to the research, development, and commercialization of proprietary technologies aimed at the medical and consumer healthcare markets. The company specializes in creating innovative biomedical products and devices with a focus on antibacterial applications. Quick-Med's core technologies include the Novel Intrinsically Micro-Bonded Utility Substrate (NIMBUS), a family of advanced polymers exhibiting antimicrobial and hemostatic properties suitable for various applications. Additionally, they offer Stay Fresh, a chemical formulation designed for textiles, providing durable antimicrobial protection against a broad spectrum of bacteria. Their MultiStat technology represents a collection of patented methods and compounds geared towards advanced skin therapy applications. Quick-Med Technologies serves a diverse clientele, including government agencies, healthcare and medical organizations, apparel and textile manufacturers, and personal care companies, providing them with specialized solutions based on their unique technology platforms. The company's focus on innovation and specialized applications positions it within the niche market of advanced antimicrobial and hemostatic technologies.
What Products and Services Does QMDT Offer?
- Develop proprietary antimicrobial technologies.
- Create hemostatic products for medical applications.
- Formulate antimicrobial solutions for textiles.
- Research and develop skin therapy products.
- Serve government agencies with specialized solutions.
- Cater to healthcare and medical companies.
- Provide solutions for the apparel and textile industry.
- Offer products for the personal care market.
How Does QMDT Make Money?
- Develop and patent proprietary technologies in the antimicrobial and hemostatic fields.
- Commercialize these technologies through direct sales to government agencies and healthcare providers.
- License technologies to companies in the textile and personal care industries.
- Generate revenue through product sales, licensing fees, and royalty agreements.
What Industry Does QMDT Operate In?
Quick-Med Technologies operates within the specialty and generic drug manufacturing industry, characterized by intense competition and stringent regulatory requirements. The market is driven by an increasing demand for advanced antimicrobial and hemostatic solutions across healthcare, textiles, and personal care sectors. Companies like Quick-Med differentiate themselves through proprietary technologies and specialized applications. The industry is subject to evolving regulatory standards and pricing pressures, requiring companies to continuously innovate and adapt to maintain competitiveness. The overall drug manufacturing industry is projected to grow, driven by aging populations and increasing healthcare expenditure.
Who Are QMDT's Key Customers?
- Government agencies requiring antimicrobial solutions.
- Healthcare and medical companies seeking advanced wound care products.
- Apparel and textile manufacturers looking for antimicrobial fabrics.
- Personal care companies developing skin therapy products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 0 purchases, 11 sales, 1 other transactions · 1 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Earnings Track Record
Quick-Med Technologies, Inc. has missed Wall Street's EPS estimate in 1 of its last 3 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 0.7% below estimates on average.
Financial Health
Quick-Med Technologies, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Quick-Med Technologies, Inc. stands at 8.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -98.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Quick-Med Technologies, Inc. operates in the Healthcare sector. It is headquartered in Gainesville, US. QMDT has traded publicly since 2002.
QMDT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
QMDT Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
QMDT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for QMDT.
Price Targets
Wall Street price target analysis for QMDT.
QMDT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for QMDT; grades run from A+ (80-100) to F (below 30).
Leadership: Gregory S. Schultz
CEO
Gregory S. Schultz serves as the CEO of Quick-Med Technologies, Inc. His background includes experience in managing small teams and guiding the strategic direction of the company. He is responsible for overseeing the development and commercialization of the company's proprietary technologies in the medical and consumer healthcare markets. His leadership is crucial for navigating the challenges of a small company operating in a competitive industry.
Track Record: Under Gregory S. Schultz's leadership, Quick-Med Technologies has focused on developing and patenting its core technologies, including NIMBUS, Stay Fresh, and MultiStat. Key milestones include securing government contracts and establishing relationships with healthcare providers. The company has also focused on exploring licensing opportunities to expand its market reach.
QMDT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Quick-Med Technologies may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial information available and may be subject to greater regulatory scrutiny. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud or manipulation. This tier contrasts sharply with exchanges like NYSE or NASDAQ, which have much stricter listing requirements.
- OTC Tier: OTC Other
- Limited Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Lack of Transparency: Limited financial information and regulatory oversight.
- Price Volatility: Potential for significant price swings due to speculative trading.
- Dilution Risk: Potential for the company to issue new shares, diluting existing shareholders' ownership.
- Going Concern Risk: Uncertainty about the company's ability to continue operating due to financial losses.
- Verify the company's financial statements and SEC filings (if any).
- Research the backgrounds of the company's management team and board members.
- Assess the company's intellectual property and patent portfolio.
- Evaluate the company's competitive landscape and market position.
- Understand the company's business model and revenue streams.
- Determine if the company is subject to any regulatory investigations or legal proceedings.
- Consult with a qualified financial advisor before investing.
- Patented Technologies: Proprietary NIMBUS, Stay Fresh, and MultiStat technologies.
- Government Contracts: Existing relationships with government agencies.
- Scientific Publications: Peer-reviewed publications supporting the efficacy of their technologies.
QMDT Healthcare Stock FAQ
What do analysts say about QMDT stock?
As of March 17, 2026, there is limited analyst coverage available for Quick-Med Technologies, Inc. due to its OTC listing and small market capitalization. Key valuation metrics, such as P/E ratio (-0.02) and profit margin (-76.8%), reflect the company's current lack of profitability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Financial data based on available public information.